As a global biopharmaceutical leader, this company pursues the mission of public health for all. It recognizes the connection between climate change and public health. Health is their business and contribution to society. Starting in 2018, it extended that ambition into its fleet by moving to convert its entire 4,800-unit fleet to low-emission hybrid vehicles. In early 2020, it announced its commitment to achieve zero carbon emissions in operations, sites, and fleet, by 2025 and carbon negative value chain by 2030.
First, the team evaluated numerous hybrids for TCO, sustainability and cost savings. This analysis identified which models were a key benefit and fit for the fleet. Next, Wheels applied the same analytics to an electric-vehicle conversion, identifying which vehicles should be the first to transition, with an eye to available vehicle choices, current infrastructure, and available charging stations. Wheels and this company took a preliminary survey of the field and found a list of possible drivers who were willing and able to make the change.
With 81% of the fleet now transitioned to hybrids and 12% to battery electric vehicles (BEV), fuel economy has improved to an impressive 35.7 MPG. By the end of 2023, the goal is to have 32% of the fleet either on order or on the road with a BEV.